Bank of New York Mellon’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.8M | Buy |
680,481
+42,823
| +7% | +$387K | ﹤0.01% | 2255 |
|
|
2026
Q1 | $6.07M | Buy |
637,658
+29,666
| +5% | +$230K | ﹤0.01% | 2204 |
|
|
2025
Q4 | $4.74M | Sell |
607,992
-11,996
| -2% | -$86.7K | ﹤0.01% | 2355 |
|
|
2025
Q3 | $4.71M | Buy |
619,988
+7,330
| +1% | +$61K | ﹤0.01% | 2356 |
|
|
2025
Q2 | $5.49M | Buy |
612,658
+22,781
| +4% | +$212K | ﹤0.01% | 2217 |
|
|
2025
Q1 | $4.42M | Sell |
589,877
-7,061
| -1% | -$57K | ﹤0.01% | 2287 |
|
|
2024
Q4 | $4.49M | Buy |
596,938
+100
| +0% | +$759 | ﹤0.01% | 2351 |
|
|
2024
Q3 | $4.54M | Sell |
596,838
-179,119
| -23% | -$1.36M | ﹤0.01% | 2333 |
|
|
2024
Q2 | $4.8M | Buy |
775,957
+86,249
| +13% | +$476K | ﹤0.01% | 2366 |
|
|
2024
Q1 | $3.5M | Sell |
689,708
-62,277
| -8% | -$350K | ﹤0.01% | 2491 |
|
|
2023
Q4 | $4.5M | Sell |
751,985
-15,586
| -2% | -$90.3K | ﹤0.01% | 2423 |
|
|
2023
Q3 | $5.43M | Buy |
767,571
+8,087
| +1% | +$58.1K | ﹤0.01% | 2270 |
|
|
2023
Q2 | $5.35M | Buy |
759,484
+88,876
| +13% | +$713K | ﹤0.01% | 2293 |
|
|
2023
Q1 | $5.59M | Sell |
670,608
-6,414
| -0.9% | -$61.7K | ﹤0.01% | 2239 |
|
|
2022
Q4 | $7.77M | Buy |
677,022
+5,610
| +0.8% | +$70K | ﹤0.01% | 2074 |
|
|
2022
Q3 | $8.46M | Buy |
671,412
+51,541
| +8% | +$663K | ﹤0.01% | 1995 |
|
|
2022
Q2 | $6.56M | Sell |
619,871
-272,237
| -31% | -$2.81M | ﹤0.01% | 2170 |
|
|
2022
Q1 | $14.5M | Buy |
892,108
+34,176
| +4% | +$548K | ﹤0.01% | 1865 |
|
|
2021
Q4 | $11.9M | Buy |
857,932
+110,111
| +15% | +$1.46M | ﹤0.01% | 2009 |
|
|
2021
Q3 | $10.7M | Buy |
747,821
+9,508
| +1% | +$150K | ﹤0.01% | 2081 |
|
|
2021
Q2 | $11.7M | Buy |
738,313
+23,412
| +3% | +$318K | ﹤0.01% | 2042 |
|
|
2021
Q1 | $7.27M | Sell |
714,901
-43,201
| -6% | -$445K | ﹤0.01% | 2264 |
|
|
2020
Q4 | $5.65M | Buy |
758,102
+31,668
| +4% | +$163K | ﹤0.01% | 2304 |
|
|
2020
Q3 | $2.5M | Sell |
726,434
-104,484
| -13% | -$448K | ﹤0.01% | 2538 |
|
|
2020
Q2 | $3.96M | Buy |
830,918
+180,280
| +28% | +$720K | ﹤0.01% | 2329 |
|
|
2020
Q1 | $1.3M | Buy |
650,638
+106,837
| +20% | +$294K | ﹤0.01% | 2790 |
|
|
2019
Q4 | $1.88M | Buy |
543,801
+109,121
| +25% | +$275K | ﹤0.01% | 2851 |
|
|
2019
Q3 | $1.25M | Sell |
434,680
-17,602
| -4% | -$54.8K | ﹤0.01% | 3040 |
|
|
2019
Q2 | $1.71M | Sell |
452,282
-450,378
| -50% | -$2.71M | ﹤0.01% | 2881 |
|
|
2019
Q1 | $7.35M | Buy |
902,660
+359,634
| +66% | +$3.08M | ﹤0.01% | 2134 |
|
|
2018
Q4 | $4.38M | Buy |
543,026
+122,201
| +29% | +$950K | ﹤0.01% | 2377 |
|
|
2018
Q3 | $3.21M | Buy |
420,825
+12,544
| +3% | +$84.3K | ﹤0.01% | 2608 |
|
|
2018
Q2 | $2.34M | Sell |
408,281
-54,089
| -12% | -$298K | ﹤0.01% | 2769 |
|
|
2018
Q1 | $2.21M | Sell |
462,370
-1,821
| -0.4% | -$9.36K | ﹤0.01% | 2754 |
|
|
2017
Q4 | $2.28M | Buy |
464,191
+94,160
| +25% | +$456K | ﹤0.01% | 2774 |
|
|
2017
Q3 | $1.94M | Buy |
370,031
+470
| +0.1% | +$2.41K | ﹤0.01% | 2858 |
|
|
2017
Q2 | $2.06M | Buy |
369,561
+8,272
| +2% | +$50.4K | ﹤0.01% | 2833 |
|
|
2017
Q1 | $3.04M | Buy |
361,289
+23,072
| +7% | +$160K | ﹤0.01% | 2600 |
|
|
2016
Q4 | $2.14M | Buy |
338,217
+19,338
| +6% | +$101K | ﹤0.01% | 2807 |
|
|
2016
Q3 | $1.41M | Buy |
318,879
+12,316
| +4% | +$49.2K | ﹤0.01% | 2986 |
|
|
2016
Q2 | $870K | Sell |
306,563
-552
| -0.2% | -$1.71K | ﹤0.01% | 3238 |
|
|
2016
Q1 | $869K | Sell |
307,115
-18,025
| -6% | -$79.9K | ﹤0.01% | 3146 |
|
|
2015
Q4 | $3.35M | Sell |
325,140
-5,403
| -2% | -$53.7K | ﹤0.01% | 2414 |
|
|
2015
Q3 | $3.77M | Sell |
330,543
-61,347
| -16% | -$819K | ﹤0.01% | 2399 |
|
|
2015
Q2 | $5.85M | Buy |
391,890
+25,926
| +7% | +$295K | ﹤0.01% | 2259 |
|
|
2015
Q1 | $3.3M | Sell |
365,964
-368
| -0.1% | -$3.81K | ﹤0.01% | 2541 |
|
|
2014
Q4 | $4.45M | Buy |
366,332
+9,122
| +3% | +$101K | ﹤0.01% | 2365 |
|
|
2014
Q3 | $3.49M | Buy |
357,210
+32,495
| +10% | +$398K | ﹤0.01% | 2523 |
|
|
2014
Q2 | $4.14M | Buy |
324,715
+233,580
| +256% | +$2.27M | ﹤0.01% | 2425 |
|
|
2014
Q1 | $964K | Sell |
91,135
-22,236
| -20% | -$237K | ﹤0.01% | 3301 |
|
|
2013
Q4 | $862K | Sell |
113,371
-7,345
| -6% | -$46.5K | ﹤0.01% | 3372 |
|
|
2013
Q3 | $878K | Buy |
120,716
+36,523
| +43% | +$185K | ﹤0.01% | 3311 |
|
|
2013
Q2 | $131K | Buy |
+84,193
| New | +$145K | ﹤0.01% | 3874 |
|
Other funds holding BCRX
N
GKIM
RHJA
Bank of New York Mellon's BCRX Position: Q2 2026 in Review
Bank of New York Mellon increased its BioCryst Pharmaceuticals (BCRX) stake by 6.7% in Q2 2026, buying an estimated $387K and bringing the position to 680,481 shares worth $6.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2255.
Bank of New York Mellon first reported a position in BCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.5M in Q1 2022. 179 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- Bank of New York Mellon held 680,481 shares of BioCryst Pharmaceuticals worth $6.8M as of Q2 2026.
- Bank of New York Mellon bought 42,823 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $387K.
- BioCryst Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2255 holding.
- Bank of New York Mellon first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's BioCryst Pharmaceuticals position peaked at $14.5M in Q1 2022.
- 179 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.